This multi-platform, pan-tumor biomarker analysis for therapeutic decision support and clinical trials matching is particularly helpful when selecting optimal treatment for patients with rare tumors or difficult-to-treat, refractory disease
Despite the widespread availability and uptake of first-, second-, and third-generation antiepileptic drugs (AEDs), approximately one-third of patients with epilepsy suffer from refractory disease
, leaving significant commercial opportunity for new and emerging drugs.
The open-label, Phase 1 dose escalation/dose expansion trial will evaluate the safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of CB-5083 in multiple myeloma patients who have relapsed/refractory or refractory disease
after receiving two or more lines of therapy, including an immunomodulatory agent (IMiD) and a proteasome inhibitor.
Radioembolization significantly prolonged overall survival compared with supportive care alone in a well-matched cohort of patients with extensive, liver-dominant chemotherapy refractory disease
for whom there are limited treatment options," said Prof.
The patients with relapsed or refractory disease
who are candidates for high-dose therapy and have a complete or partial response to such therapy also may be considered for a clinical trial, which could include the option of an allogeneic stem cell transplant.
Multiple myeloma patients with relapsed and refractory disease
are underserved by current pharmaceutical offerings.
Based on data available to date, 60% of patients experienced a stabilization of their highly refractory disease
with a local response rate of 50% observed in the 10 evaluable patients, notably 3 complete responses (CR), 2 partial responses (PR) and 1 patient with stable disease (SD).
Dr Topp - Acute Lymphocytic Leukemia: impressive results with a bispecific antibody in patients with refractory disease
Nicotine, in fact, has been proposed as a treatment for ulcerative colitis, and appendectomy has been proposed as treatment for refractory disease
The NDS is based on results from a pivotal trial in HL patients with relapsed or refractory disease
following an autologous stem cell transplant (ASCT) and a pivotal trial in relapsed or refractory sALCL patients.
The Company's pipeline includes promising early and late-stage drug candidates with unique formulations and mechanisms of action that address the needs of seriously ill patients, such as at-home chemotherapy and new treatment regimens for refractory disease
Based on data available to date, a local response rate of 80% has been observed in the 5 evaluable patients with refractory disease
, notably 2 complete responses (CR), 2 partial responses (PR) and 1 patient with stable disease (SD).